indazoles has been researched along with Metabolic Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cebrián, D; de Cabo, R; González-García, I; Gutierrez, VM; Iglesias, G; López, M; Lopez-Guadamillas, E; Martinez, S; Mattison, JA; Mitchell, SJ; Muñoz-Martin, M; Ortega-Molina, A; Pastor, J; Serrano, M; Szarowicz, MD; Vaughan, KL | 1 |
| Greenhill, C | 1 |
2 other study(ies) available for indazoles and Metabolic Syndrome
| Article | Year |
|---|---|
Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.
Topics: Adiposity; Animals; Histological Techniques; Imidazoles; Immunoblotting; Indazoles; Liver; Macaca mulatta; Mass Spectrometry; Metabolic Syndrome; Mice, Obese; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; Sulfonamides | 2015 |
Obesity: Inhibiting PI3K reduces body weight in obese mice.
Topics: Adiposity; Animals; Imidazoles; Indazoles; Metabolic Syndrome; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; Sulfonamides | 2015 |